ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 885
2 570
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JP |
|
ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
|
59.8B JPY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
992.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
541.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
271.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
95.6B EUR |
Loading...
|
Market Distribution
| Min | -125 500% |
| 30th Percentile | 4.2% |
| Median | 7% |
| 70th Percentile | 10.6% |
| Max | 9 743.7% |
Other Profitability Ratios
ASKA Pharmaceutical Holdings Co Ltd
Glance View
ASKA Pharmaceutical Holdings Co., Ltd. engages in the management of its group companies which are involved in the manufacture and sale of pharmaceuticals, quasi-drugs, food, veterinary drugs, feeds, feed additives, and medical devices. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2021-04-01. The firm mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for ASKA Pharmaceutical Holdings Co Ltd is 8.3%, which is below its 3-year median of 9.2%.
Over the last 3 years, ASKA Pharmaceutical Holdings Co Ltd’s Operating Margin has increased from 6.4% to 8.3%. During this period, it reached a low of 6.4% on Aug 30, 2022 and a high of 10.7% on Sep 30, 2024.